SCHEMBL3014628

SCHEMBL3014628

Cc1cccc(C)c1Cc1csc(N2CCC(S(=O)(=O)c3cccc(Cl)c3Cl)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSS P25774 7/20 0.43
AURKA O14965 1/20 0.35
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
DCTPP1 Q9H773 1/20 0.34
HSD11B1 P28845 2/20 0.34
HSD17B1 P14061 1/20 0.34
HSD17B2 P37059 1/20 0.34
LMNA P02545 2/20 0.33
KMT2A Q03164 2/20 0.33
TSHR P16473 1/20 0.33
PTPN11 Q06124 1/20 0.32
NPC1 O15118 1/20 0.32
MEN1 O00255 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003812 0.94 CTSS (0.41) CTSSAURKAAURKBINCENPRAB9A
SCHEMBL3016908 0.93 CTSS (0.44) CTSSRAB9ASMN1; SMN2DCTPP1HSD11B1
SCHEMBL3016119 0.91 CTSS (0.42) CTSSAURKAAURKBINCENPRAB9A
SCHEMBL3007503 0.90 CTSS (0.41) CTSSAURKAAURKBINCENPRAB9A
SCHEMBL3018933 0.88 CTSS (0.42) CTSSAURKAAURKBINCENPRAB9A
SCHEMBL3022762 0.88 LMNA (0.36) CTSSRAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL3005760 0.87 CTSS (0.41) CTSSAURKAAURKBINCENPRAB9A
SCHEMBL3015090 0.87 CTSS (0.42) CTSSAURKAAURKBINCENPRAB9A
SCHEMBL3019338 0.87 CTSS (0.38) CTSSRAB9ASMN1; SMN2
SCHEMBL3011124 0.87 SMN1; SMN2 (0.37) CTSSRAB9ASMN1; SMN2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885AURKA 4376/4885AURKB 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.